drugset
drugset / Trial / NCT05501288

Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019

NCT05501288 ↗

Completed 108 enrolled Shanghai Children's Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators conducted a single-center, open-label, parallel-group randomized controlled trial to assess the efficacy and safety of a Chinese herb compound granule Huashi Baidu granule (HSBDG) in pediatric patients with laboratory-confirmed mild COVID-19. 108 recruited children (aged 3 to 18 years) with laboratory-confirmed mild COVID-19 were randomly allocated 2:1 to receive oral HSBDG for 5 consecutive days (intervention group) and to receive compound pholcodine oral solution for 5 consecutive days (control group). The negative conversion time of SARS-CoV-2 nucleic acid and symptom scores were recorded.

Timeline

Start
2022-05-01
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Huashibaidu granule Traditional medicine (herbal / TCM) 2.5 g Oral
Subject Huashibaidu granule Traditional medicine (herbal / TCM) 5 g Oral
Subject Huashibaidu granule Traditional medicine (herbal / TCM) 10 g Oral
Subject compound pholcodine oral solution Unknown 5 ml Oral
Subject compound pholcodine oral solution Unknown 10 ml Oral

Indications

COVID-19